A Randomised, Double Blind, Placebo Controlled Study of the Efficacy and Safety of Angiotensin Therapeutic Vaccine (ATV) in Subjects With Mild to Moderate Hypertension.
Phase of Trial: Phase II
Latest Information Update: 03 Aug 2016
At a glance
- Drugs Angiotensin inhibitor vaccine (Primary) ; CoVaccineHT
- Indications Hypertension
- Focus Therapeutic Use
- Sponsors BTG; Protherics
- 10 Jun 2017 Biomarkers information updated
- 07 Apr 2009 Status changed from recruiting to active, no longer recruiting, as reported in ClinicalTrials.gov record.
- 02 Apr 2009 Dosing has been suspended for 2-3 months while safety data are reviewed, according to a BTG plc media release.